Prevalence of Cannabis Use and Cannabis Route of Administration among Massachusetts Adults in Buprenorphine Treatment for Opioid Use Disorder
Bibliographic Data
| ID | 21645261 |
|---|---|
| Authors | Joanna M Streck (0000-0002-7842-9080, Massachusetts General Hospital, corresponding author), Susan Regan (0000-0003-0940-2017, Massachusetts General Hospital), Benjamin Bearnot (0000-0002-2554-8422, Massachusetts General Hospital), Priya S Gupta (0000-0002-4584-1968, Massachusetts General Hospital), Sara Kalkhoran (0000-0002-1815-3828, Massachusetts General Hospital), Kelly M Kalagher (0000-0002-5136-5689, Massachusetts General Hospital), Sarah E Wakeman (0000-0002-5475-2713, Massachusetts General Hospital), Sarah Wakeman (Massachusetts General Hospital), Nancy A Rigotti (0000-0002-2223-1657, Massachusetts General Hospital) |
| Year | 2022 |
| Volume | 57 |
| Issue | 7 |
| Pages | 1104-1110 |
| Publication date | 2022-06-07 |
| Peer Reviewed | Yes |
| Open Access | No |
| Type | ARTICLE |
| Venue | Substance Use & Misuse (JOURNAL) |
| Journal identifiers | ISSN: 1082-6084 • E-ISSN: 1532-2491 |
| Publisher | Informa UK Limited (PUBLISHER • GB) |
| DOI | 10.1080/10826084.2022.2063899 |
| PMID | 35410577 |
| OpenAlex | W4223480735 |
| Language | EN |
| References cited | 35 |
BACKGROUND: Recent prevalence estimates of cannabis use among individuals receiving medication treatment for OUD (MOUD) are lacking, and no study has characterized cannabis route of administration (cROA) in this population. These knowledge gaps are relevant because cannabis' effects and health outcomes vary by cROA and the availability and perceptions of cROA (e.g., vaping devices) are changing. METHODS: The Vaping In Buprenorphine-treated patients Evaluation (VIBE) cross-sectional survey assessed the prevalence and correlates of cannabis use and cROA among adults receiving buprenorphine MOUD from 02/20 to 07/20 at five community health centers in Massachusetts, a state with legal recreational and medical cannabis use. RESULTS: Among the 92/222 (41%) respondents reporting past 30-day cannabis use, smoking was the most common cROA (75%), followed by vaping (38%), and eating (26%). Smoking was more often used as a single cROA vs. in combination others (p = 0.01), whereas vaping, eating, and dabbing were more often used in combination with another cROA (all p < 0.05). Of the 39% of participants reporting multiple cROA, smoking and vaping (61%), and smoking and eating (50%), were the most prevalent combinations. Nonwhite race (vs. white) and current cigarette smoking (vs. no nicotine use) were associated with past 30-day cannabis use in multiple logistic regression. CONCLUSIONS: Prevalence of past 30-day cannabis use among individuals receiving buprenorphine MOUD in Massachusetts in 2020 was nearly double the prevalence of cannabis use in Massachusetts' adult general population in 2019 (21%). Our data are consistent with state and national data showing smoking as the most common cROA
Buprenorphine · Cannabis · Drug · Illicit drug · Opioid · Opioid use disorder · Psychiatry · Young adult · Cannabis and Cannabinoid Research · Medicine · Opioid Use Disorder Treatment · Psychology · Substance Abuse Treatment and Outcomes · Gerontology · Internal Medicine
Determinants of Tobacco Use and Renaming the FTND to the Fagerstrom Test for Cigarette Dependence
The Audit Alcohol Consumption Questions (Audit-C) An Effective Brief Screening Test for Problem Drinking
A Brief Measure for Assessing Generalized Anxiety Disorder
The PHQ-8 as a measure of current depression in the general population
Routes of administration for cannabis use – basic prevalence and related health outcomes
Trends in Daily Cannabis Use Among Cigarette Smokers
| Citation velocity | historical |
|---|---|
| Highly cited | No |